Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock - CYCCP STOCK NEWS

Cyclacel Pharmaceuticals, Inc. announces preclinical data supporting the development of fadraciclib, a novel CDK2/9 inhibitor, in patients with solid tumors and lymphoma. The data will be presented at the AACR Annual Meeting 2024, showcasing the activity and antitumor effects of fadraciclib in various cancer cell lines.

Cyclacel Pharmaceuticals, Inc. receives £2.3 million R&D tax credit from HMRC, providing non-dilutive capital for innovative cancer treatments.

Cyclacel Pharmaceuticals, Inc. announces CEO's presentation at the 2024 BIO CEO & Investor Conference. The presentation will cover business overview and programs, with meetings available for conference attendees.

Cyclacel Pharmaceuticals, Inc. announces the appointment of Dr. Brian Schwartz as the interim Chief Medical Officer, succeeding Dr. Mark Kirschbaum. Dr. Schwartz brings extensive clinical and product development experience in oncology and hematology. The company plans to enter mid-stage development following recent discoveries of potential precision medicine approaches for its clinical candidates, oral fadraciclib and oral plogosertib. Dr. Schwartz's experience is expected to guide the team to deliver key value inflection milestones and communicate these to the investment community as the company advances its business strategy.

Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring continued listing on the Nasdaq Capital Market.

Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) announced that Spiro Rombotis, President & CEO, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase on January 8-10, 2024, in San Francisco, California.

Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) announced a registered direct offering of 388,200 shares of common stock at $3.315 per share, along with unregistered warrants to purchase up to 388,200 shares at $3.19 per share, expected to close on Dec. 22, 2023.

Cyclacel Pharmaceuticals, Inc. (CYCC) announced positive interim results from its Phase 1 study of fadraciclib (fadra) in patients with advanced solid tumors and lymphoma. Fadra showed promising anticancer activity as a single agent, especially in patients with CDKN2A, CDKN2B and/or MTAP deletions. The company also reported encouraging results from its plogosertib dose escalation study.

Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) will implement a 1-for-15 Reverse Stock Split of its common stock to comply with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. The Reverse Stock Split will reduce the outstanding common stock from approximately 12.6 million shares to approximately 0.84 million shares, impacting all holders of the Company’s common stock proportionally. Equiniti Trust Company, LLC, is acting as exchange agent for the Reverse Stock Split.